said it would close its Houston plant in December 2007 in a cost-cutting move.
The Norcross, Ga., company, which bills itself as the global leader in providing automated instrument-reagent systems to the blood transfusion industry, cited the expense of operating two FDA-licensed manufacturing facilities.
"This was a difficult decision because we value our Houston employees who have worked very hard over the years," said President Gioacchino De Chirico. "However, it represents another major step in our continuous efforts to reduce costs and increase our gross margins."
The company sees an after-tax charge of $2 million to $3 million over the next two years, including about $1.5 million to $2 million in the fiscal second quarter ending Nov. 30.